Dose-finding trial of a combined regsimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An italian oncology group for clinical research (GOIRC) study

Journal of Immunotherapy

Volumn 33, Issue 7, 2010, Pages 735-741

  Buti, Sebastiano ^a   Lazzarelli, Silvia ^a   Chiesa, Matteo Dalla ^a   Simonelli, Cecilia ^b   Lo Re, Giovanni ^c   Lheshi, Arvin ^b   Simon, Spazzapan ^b   Mattioli, Rodolfo ^d   Caminiti, Caterina ^e   Mazza, Giancarlo ^f   Donini, Maddalena ^a   Passalacqua, Rodolfo ^a  

^a Oncology Division   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

^f Radiology Unit   (Italy)

Author keywords

advanced kidney cancer; antiangiogenic; chemoimmunitherapy; combination

Indexed keywords

ANTIHISTAMINIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CORTISONE; FLUOROURACIL; FLUOROURACILE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 2; SUNITINIB; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHROMYALGIA; ARTICLE; ASTHENIA; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PAIN; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DYSPNEA; EPISTAXIS; EVENING DOSAGE; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOPENIA; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MACROHEMATURIA; MALAISE; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; SHIVERING; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTENTION TO TREAT ANALYSIS; INTERFERON-ALPHA; INTERLEUKIN-2; ITALY; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 77955176213     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181eb8289     Document Type: Article

References (48)

1. Stewart SL, King JB, Thompson TD, et al. Cancer mortality surveillance-United States, 1990-2000. MMWR Surveill Summ. 2004;53:100-108.
2. Tolia BM, Whitmore WF. Solitary metastasis from renal cell carcinoma. J Urol. 1975;114:836-838.
3. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrec-tomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med. 2001;345:1655-1659.
4. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119-1132.
5. Lilleby W, Fossa SD. Chemotherapy in metastatic renal cell cancer. World J Urol. 2005;23:175-179.
6. Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol. 2005; 16:7-15.
7. Cameron RB, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recom-binant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res. 1988;48:5810-5817.
8. Iigo M, Sakurai M, Tamura T, et al. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngenic murine tumors. Cancer Res. 1988;48:260-264.
9. Buzio C, Andrulli S, Santi R, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer. 2001;92:2286-2296.
10. Passalacqua R, Buzio C, Buti S, et al. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. Cancer Immunol Immunother. 2009;25: DOI 10.1007/s00262-009-0773-779
11. Stadler WM, Vogelzang NJ. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol. 1995;22:67-73.
12. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleu-kin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol. 1993;11:1809-1816.
13. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immuno-therapie. N Engl J Med. 1998;338:1272-1278.
14. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28:488-495.
15. Buti S, Brighenti M, Bongiovanni C, et al. Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemo-immunotherapy in metastatic renal cell cancer. J Immunother. 2007;30:780-786.
16. Yagoda A. Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol. 1989;7:199-206.
17. Buzaid AC, Todd MB. Therapeutic options in renal cell carcinoma. Semin Oncol. 1989;16(1, suppl 1):12-19.
18. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
19. Motl S. Bevacizumabin combination chemotherapy for colo-rectal and other cancers. Am J Health Syst Pharm. 2005;62: 1021-1032.
20. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349: 427-434.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
22. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997;89:1138-1147.
23. NCI Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Publish Date: December 12, 2003. http://ctep.cancer. gov/reporting/ctc.html.
24. Motzer RJ, Bacik J, Mhurphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20: 289-296.
25. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
26. Escudier B, Eisen T, Stadlre WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356: 125-134.
27. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
28. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422-5428.
29. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068.
30. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007;356:2271-2281.
31. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
32. Rini BI, Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and Capecitabine in metastatic renal cell carcinoma. Cancer. 2005;103:553-558.
33. Tannir NM, Thall PF, Ng CS, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008;180:867-872.
34. Soga N, Yamada Y, Nishikawa K, et al. Gemcitabine and capecitabine chemotherapy in Japanese patients with immuno-therapy-resistant renal cell carcinoma. Int J Urol. 2009;16: 576-579.
35. Tempero M, Plunkett W, Ruiz Van Haperen VW, et al. Randomized phase II comparison of dose-intense gemcita-bine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-3408.
36. Cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol. 2001;152:1197-1206.
37. Palumbo R, Sampaolesi M, De Marchis F, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004;164: 441-449.
38. Dumitriu IE, Baruah P, Bianchi ME, et al. Requirement of HMGB1 and RAGE for the maturation of human plasma-cytoid dendritic cells. Eur J Immunol. 2005;35:2184-2190.
39. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 2004;173:307-313.
40. Lehner MD, Morath S, Michelsen KS, et al. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different toll-like receptors independent of paracrine mediators. J Immunol. 2001;166:5161-5167.
41. Zacharowski K, Frank S, Otto M, et al. Lipoteichoic acid induces delayed protection in the rat heart: a comparison with endotoxin. Arterioscl Thromb Vasc Biol. 2000;20:1521-1528.
42. Rouhiainen A, Tumova S, Valmu L, et al. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol. 2007;81:49-58.
43. Zimmermann K, Volkel D, Pable S, et al. Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation. 2004;28:221-229.
44. Hreggvidsdottir HS, Ostberg T, Wahamaa H, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol. 2009;86:655-662.
45. Cavaillon JM, Adrie C, Fitting C, et al. Endotoxin tolerance: is there a clinical relevance? J Endotoxin Res. 2003;9:101-107.
46. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 2006;290:C917-C924.
47. Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005;61:1-9.
48. 3Cys is due to ablation of IL-1R-associated kinase-1. J Immunol. 2004;173:2736-2745.